METABOLOMICS USED TO DISCOVER BIOMARKERS FOR PERIODONTAL DISEASE
RESEARCH TRIANGLE PARK, N.C. (September 29, 2009) — Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced a new study has been published identifying biomarkers for periodontitis and gingivitis. Co-authored by scientists at Colgate-Palmolive, The Forsyth Institute and Metabolon, the paper, “Acceleration of Purine Degradation Pathway by Periodontal Disease”, appears in the Journal of Dental Research (Volume 88, No. 9, 851-855 (September 2009)).
Using Metabolon’s biochemical profiling technology, mechanistically-linked biomarkers were discovered and validated from the cervicular fluid of patients suffering from periodontitis and gingivitis. Several hundred biochemicals were identified in a few microliters of the crevicular fluid found between the tooth and gums. The biomarkers suggest that the diseases are mediated by enhanced purine degradation, a biochemical pathway associated with reactive oxygen species production and cellular inflammation
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com.